Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to PET ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Biology and evolution of poorly differentiated neuroendocrine tumors.Nat Med. 2017; 23: 664-673
- Neuroendocrine neoplasm update: toward universal nomenclature.Endocr Relat Cancer. 2020; 27: R211-R218
- Advances in the diagnosis and management of well-differentiated neuroendocrine neoplasms.Endocr Rev. 2020; 41: 371-403
- The genomic landscape of 85 advanced neuroendocrine neoplasms reveals subtype-heterogeneity and potential therapeutic targets.Nat Commun. 2021; 12: 4612
- An organoid biobank of neuroendocrine neoplasms enables genotype-phenotype mapping.Cell. 2020; 183: 1420-1435
- Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Ann Oncol. 2020; 31: 844-860
- A comprehensive assessment of the role of miRNAs as biomarkers in gastroenteropancreatic neuroendocrine tumors.Neuroendocrinology. 2018; 107: 73-90
- MicroRNAs, long non-coding RNAs, and circular RNAs: potential biomarkers and therapeutic targets in pheochromocytoma/paraganglioma.Cancers (Basel). 2021; 13: 1522
- Towards a new classification of gastroenteropancreatic neuroendocrine neoplasms.Nat Rev Clin Oncol. 2016; 13: 691-705
- The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms.Endocr Relat Cancer. 2022; 29: 1-14
- Decoding the molecular and mutational ambiguities of gastroenteropancreatic neuroendocrine neoplasm pathobiology.Cell Mol Gastroenterol Hepatol. 2015; 1: 131-153
- The molecular genetics of gastroenteropancreatic neuroendocrine tumors.Cancer Interdiscip Int J Am Cancer Soc. 2005; 104: 2292-2309
- Mutation and expression analyses reveal differential subcellular compartmentalization of PTEN in endocrine pancreatic tumors compared to normal islet cells.Am J Pathol. 2000; 157: 1097-1103
- Gene amplifications in well-differentiated pancreatic neuroendocrine tumors inactivate the p53 pathway.Genes Cancer. 2010; 1: 360-368
- Comparative genomic hybridization identifies loss of 18q22-qter as an early and specific event in tumorigenesis of midgut carcinoids.Am J Pathol. 2001; 158: 1803-1808
- Alterations of the SDHD gene locus in midgut carcinoids, Merkel cell carcinomas, pheochromocytomas, and abdominal paragangliomas.Genes Chromosomes Cancer. 2002; 34: 325-332
- The genomic landscape of small intestine neuroendocrine tumors.J Clin Invest. 2013; 123: 2502-2508
- The evolving (epi) genetic landscape of pancreatic neuroendocrine tumours.Endocr Relat Cancer. 2019; 26: R519-R544
- Aberrant hypermethylation of tumor suppressor genes in pancreatic endocrine neoplasms.Ann Surg. 2003; 238: 423
- Microsatellite instability and gene mutations in transforming growth factor-beta type II receptor are absent in small bowel carcinoid tumors.Cancer. 2005; 103: 229-236
- EZH2 inhibition as new epigenetic treatment option for pancreatic neuroendocrine neoplasms (PanNENs).Cancers (Basel). 2021; 13: 5014
- EZH2 presents a therapeutic target for neuroendocrine tumors of the small intestine.Sci Rep. 2021; 11: 22733
- DNA methyltransferases 1, 3a, and 3b overexpression and clinical significance in gastroenteropancreatic neuroendocrine tumors.Hum Pathol. 2010; 41: 1069-1078
- DNA methylation profiles distinguish different subtypes of gastroenteropancreatic neuroendocrine tumors.Epigenomics. 2015; 7: 1245-1258
- DNA methylation reveals distinct cells of origin for pancreatic neuroendocrine carcinomas and pancreatic neuroendocrine tumors.Genome Med. 2022; 14: 1-14
- Genome methylation accurately predicts neuroendocrine tumor origin: an online tool.Clin Cancer Res. 2021; 27: 1341-1350
- Multiple endocrine neoplasia type 1 gene maps to chromosome 11 and is lost in insulinoma.Nature. 1988; 332: 85-87
- Von Hippel-Lindau disease: recent genetic progress and patient management. Francophone Study Group of von Hippel-Lindau Disease (GEFVH).Ann Endocrinol (Paris). 1998; 59: 452-458
- DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors.Science. 2011; 331: 1199-1203
- Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors.Gastroenterology. 2014; 146: 453-460
- Whole-genome landscape of pancreatic neuroendocrine tumours.Nature. 2017; 543: 65-71
- Comprehensive genomic profiling of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs).Clin Cancer Res. 2020; 26: 5943-5951
- Mechanisms of genomic instabilities underlying two common fragile-site-associated loci, PARK2 and DMD, in germ cell and cancer cell lines.Am J Hum Genet. 2010; 87: 75-89
- Dystrophin deficiency leads to genomic instability in human pluripotent stem cells via NO synthase-induced oxidative stress.Cells. 2019; 8: 53
- Dynamic epigenetic regulation by menin during pancreatic islet tumor formation.Mol Cancer Res. 2015; 13: 689-698
- Genetic and epigenetic drivers of neuroendocrine tumours (NET).Endocr Relat Cancer. 2017; 24: R315-R334
- Crebbp loss drives small cell lung cancer and increases sensitivity to HDAC inhibition.Cancer Discov. 2018; 8: 1422-1437
- Global hypomethylation and promoter methylation in small intestinal neuroendocrine tumors: an in vivo and in vitro study.Epigenetics. 2014; 9: 987-997
- DNA methylation patterns identify subgroups of pancreatic neuroendocrine tumors with clinical association.Commun Biol. 2021; 4: 1-11
- CpG island methylation in carcinoid and pancreatic endocrine tumors.Oncogene. 2003; 22: 924-934
- O6-Methylguanine-DNA methyltransferase status in neuroendocrine tumours: prognostic relevance and association with response to alkylating agents.Br J Cancer. 2015; 112: 523-531
- VHL inactivation is an important pathway for the development of malignant sporadic pancreatic endocrine tumors.Endocr Relat Cancer. 2009; 16: 1219-1227
- Distinct genome-wide methylation patterns in sporadic and hereditary nonfunctioning pancreatic neuroendocrine tumors.Cancer. 2019; 125: 1247-1257
- Somatic mutation of CDKN1B in small intestine neuroendocrine tumors.Nat Genet. 2013; 45: 1483-1486
- Prognostic impact of novel molecular subtypes of small intestinal neuroendocrine tumor.Clin Cancer Res. 2016; 22: 250-258
- Expression profiling of small intestinal neuroendocrine tumors identifies subgroups with clinical relevance, prognostic markers and therapeutic targets.Mod Pathol. 2016; 29: 616-629
- Mutational and copy number asset of primary sporadic neuroendocrine tumors of the small intestine.Virchows Arch. 2018; 473: 709-717
- A hereditary form of small intestinal carcinoid associated with a germline mutation in inositol polyphosphate multikinase.Gastroenterology. 2015; 149: 67-78
- A MUTYH germline mutation is associated with small intestinal neuroendocrine tumors.Endocr Relat Cancer. 2017; 24: 427-443
- Association of DNA methylation and epigenetic inactivation of RASSF1A and beta-catenin with metastasis in small bowel carcinoid tumors.Endocrine. 2006; 30: 299-306
- TCEB3C a putative tumor suppressor gene of small intestinal neuroendocrine tumors.Endocr Relat Cancer. 2014; 21: 275-284
- Global DNA methylation patterns through an array-based approach in small intestinal neuroendocrine tumors.Endocr Relat Cancer. 2014; 21: L5-L7
- Hypomethylation of LINE-1 and Alu in well-differentiated neuroendocrine tumors (pancreatic endocrine tumors and carcinoid tumors).Mod Pathol. 2007; 20: 802-810
- Decrease of 5-hydroxymethylcytosine and TET1 with nuclear exclusion of TET2 in small intestinal neuroendocrine tumors.BMC Cancer. 2018; 18: 764
- Genetic characteristics of colorectal neuroendocrine carcinoma: more similar to colorectal adenocarcinoma.Clin Colorectal Cancer. 2021; 20: 177-185.e113
- Epigenetic EGFR gene repression confers sensitivity to therapeutic BRAFV600E blockade in colon neuroendocrine carcinomas.Clin Cancer Res. 2020; 26: 902-909
- Identification of high-risk human papillomavirus and Rb/E2F pathway genomic alterations in mutually exclusive subsets of colorectal neuroendocrine carcinoma.Mod Pathol. 2019; 32: 290-305
- Classification of pulmonary neuroendocrine tumors: new insights.Translational Lung Cancer Res. 2017; 6: 513
- Most high-grade neuroendocrine tumours of the lung are likely to secondarily develop from pre-existing carcinoids: innovative findings skipping the current pathogenesis paradigm.Virchows Arch. 2018; 472: 567-577
- Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids.Nat Commun. 2014; 5: 1-7
- Outcome and surgical strategy in bronchial carcinoid tumors: single institution experience with 252 patients.Eur J Cardiothorac Surg. 2007; 31: 186-191
- Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin-remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D.J Pathol. 2017; 241: 488-500
- Integrative genomic characterization identifies molecular subtypes of lung carcinoids.Cancer Res. 2019; 79: 4339-4347
- Specific genomic alterations in high-grade pulmonary neuroendocrine tumours with carcinoid morphology.Neuroendocrinology. 2021; 111: 158-169
- Integrative and comparative genomic analyses identify clinically relevant pulmonary carcinoid groups and unveil the supra-carcinoids.Nat Commun. 2019; 10: 1-21
- MEN1 gene mutation and reduced expression are associated with poor prognosis in pulmonary carcinoids.J Clin Endocrinol Metab. 2014; 99: E374-E378
- Comprehensive genomic profiles of small cell lung cancer.Nature. 2015; 524: 47-53
- Driver gene mutations of non-small-cell lung cancer are rare in primary carcinoids of the lung: NGS study by ion Torrent.Lung. 2015; 193: 303-308
- Typical and atypical carcinoid tumors of the lung are characterized by 11q deletions as detected by comparative genomic hybridization.Am J Pathol. 1998; 153: 1089-1098
- Molecular and cellular biology of neuroendocrine lung tumors: evidence for separate biological entities.Biochim Biophys Acta (BBA)-Reviews Cancer. 2012; 1826: 255-271
- Next-generation sequencing of pulmonary large cell neuroendocrine carcinoma reveals small cell carcinoma–like and non–small cell carcinoma–like subsets.Clin Cancer Res. 2016; 22: 3618-3629
- Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors.Nat Commun. 2018; 9: 1-13
- Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer.Nat Genet. 2012; 44: 1111-1116
- Molecular subtypes of pulmonary large-cell neuroendocrine carcinoma predict chemotherapy treatment outcome.Clin Cancer Res. 2018; 24: 33-42
- Prevalence and prognostic value of PD-L1 expression in molecular subtypes of metastatic large cell neuroendocrine carcinoma (LCNEC).Lung Cancer. 2019; 130: 179-186
- High resolution chromosome 3p allelotyping of human lung cancer and preneoplastic/preinvasive bronchial epithelium reveals multiple, discontinuous sites of 3p allele loss and three regions of frequent breakpoints.Cancer Res. 2000; 60: 1949-1960
- FGFR1 is critical for RBL2 loss–driven tumor development and requires PLCG1 activation for continued growth of small cell lung cancer.Cancer Res. 2020; 80: 5051-5062
- Mutational analysis of pulmonary tumours with neuroendocrine features using targeted massive parallel sequencing: a comparison of a neglected tumour group.Br J Cancer. 2015; 113: 1704-1711
- MYC drives temporal evolution of small cell lung cancer subtypes by reprogramming neuroendocrine fate.Cancer Cell. 2020; 38: 60-78
- Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data.Nat Rev Cancer. 2019; 19: 289-297
- Killing SCLC: insights into how to target a shapeshifting tumor.Genes Dev. 2022; 36: 241-258
- Are neuroendocrine negative small cell lung cancer and large cell neuroendocrine carcinoma with WT RB1 two faces of the same entity?.Lung Cancer Manag. 2019; 8: LMT13
- NOTCH, ASCL1, p53 and RB alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas.Int J Cancer. 2016; 138: 927-938
- DLL3 expression in large cell neuroendocrine carcinoma (LCNEC) and association with molecular subtypes and neuroendocrine profile.Lung Cancer. 2019; 138: 102-108
- Intratumoural heterogeneity generated by Notch signalling promotes small-cell lung cancer.Nature. 2017; 545: 360-364
- Genomic amplification of CD274 (PD-L1) in small-cell lung cancer.Clin Cancer Res. 2017; 23: 1220-1226
- Phosphatidylinositol-3-kinase α catalytic subunit gene somatic mutations in bronchopulmonary neuroendocrine tumours.Oncol Rep. 2012; 28: 1559-1566
- A DNA hypomethylation signature predicts antitumor activity of LSD1 inhibitors in SCLC.Cancer Cell. 2015; 28: 57-69
- Unravelling the biology of SCLC: implications for therapy.Nat Rev Clin Oncol. 2017; 14: 549-561
- EZH2 promotes progression of small cell lung cancer by suppressing the TGF-β-Smad-ASCL1 pathway.Cell Discov. 2015; 1: 1-17
- DNA methylation profiles of lung tumors1.Mol Cancer Ther. 2001; 1: 61-67
- ZAR1 is a novel epigenetically inactivated tumour suppressor in lung cancer.Clin Epigenetics. 2017; 9: 1-12
- The DNA methylation landscape of small cell lung cancer suggests a differentiation defect of neuroendocrine cells.Oncogene. 2013; 32: 3559-3568
- Different roles for caveolin-1 in the development of non-small cell lung cancer versus small cell lung cancer.Cancer Res. 2004; 64: 4277-4285
- Gene expression profiling of lung atypical carcinoids and large cell neuroendocrine carcinomas identifies three transcriptomic subtypes with specific genomic alterations.J Thorac Oncol. 2019; 14: 1651-1661
- MEN1 deficiency leads to neuroendocrine differentiation of lung cancer and disrupts the DNA damage response.Nat Commun. 2020; 11: 1-12
- Pheochromocytoma and paraganglioma.N Engl J Med. 2019; 381: 552-565
- Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A.Nature. 1993; 363: 458-460
- Identification of the von Hippel-Lindau disease tumor suppressor gene.Science. 1993; 260: 1317-1320
- Clinical and genetic characteristics of patients with neurofibromatosis type 1.N Engl J Med. 2006; 1: 2729-2731
- Comprehensive molecular characterization of pheochromocytoma and paraganglioma.Cancer Cell. 2017; 31: 181-193
- Epigenetic and metabolic reprogramming of SDH-deficient paragangliomas.Endocr Relat Cancer. 2020; 27: R451-R463
- Pheochromocytomas: the (pseudo)-hypoxia hypothesis.Best Pract Res Clin Endocrinol Metab. 2010; 24: 957-968
- Somatic mutations in H-RAS in sporadic pheochromocytoma and paraganglioma identified by exome sequencing.J Clin Endocrinol Metab. 2013; 98: E1266-E1271
- A germline mutation of the KIF1Bβ gene on 1p36 in a family with neural and nonneural tumors.Hum Genet. 2008; 124: 279-285
- Germline mutations in TMEM127 confer susceptibility to pheochromocytoma.Nat Genet. 2010; 42: 229-233
- Recurrent mutations of chromatin-remodeling genes and kinase receptors in pheochromocytomas and paragangliomas.Clin Cancer Res. 2016; 22: 2301-2310
- Whole-exome sequencing identifies somatic ATRX mutations in pheochromocytomas and paragangliomas.Nat Commun. 2015; 6: 6140
- Genomic landscape of pheochromocytoma and paraganglioma.Trends Cancer. 2018; 4: 6-9
- The Hedgehog and Wnt signalling pathways in cancer.Nature. 2001; 411: 349-354
- Wnt, Notch, and TGF-β pathways impinge on hedgehog signaling complexity: an open window on cancer.Front Genet. 2019; 10: 711
- SDH mutations establish a hypermethylator phenotype in paraganglioma.Cancer Cell. 2013; 23: 739-752
- Global DNA methylation analysis identifies two discrete clusters of pheochromocytoma with distinct genomic and genetic alterations.Sci Rep. 2017; 7: 44943
- Gain-of-function mutations in DNMT3A in patients with paraganglioma.Genet Med. 2018; 20: 1644-1651
- Metabologenomics of phaeochromocytoma and paraganglioma: an integrated approach for personalised biochemical and genetic testing.Clin Biochemist Rev. 2017; 38: 69
- DNA methylation profiling in pheochromocytoma and paraganglioma reveals diagnostic and prognostic markers.Clin Cancer Res. 2015; 21: 3020-3030
- Methylation of the p16INK4A promoter is associated with malignant behavior in abdominal extra-adrenal paragangliomas but not pheochromocytomas.Endocr Relat Cancer. 2008; 15: 609
- Acquired hypermethylation of the P16INK4A promoter in abdominal paraganglioma: relation to adverse tumor phenotype and predisposing mutation.Endocr Relat Cancer. 2013; 20: 65-78
- PI3K-AKT-mTOR-signaling and beyond: the complex network in gastroenteropancreatic neuroendocrine neoplasms.Theranostics. 2014; 4: 336-365
- ENETS consensus guidelines for the standards of care in neuroendocrine tumors: radiological, nuclear medicine and hybrid imaging.Neuroendocrinology. 2017; 105: 212-244
- Imaging of chemokine receptor 4 expression in neuroendocrine tumors-a triple tracer comparative approach.Theranostics. 2017; 7: 1489
- Inverse expression of somatostatin and CXCR4 chemokine receptors in gastroenteropancreatic neuroendocrine neoplasms of different malignancy.Oncotarget. 2015; 6: 27566
- A liquid biopsy for bronchopulmonary/lung carcinoid diagnosis.Oncotarget. 2018; 9: 7182
- A meta-analysis of the accuracy of a neuroendocrine tumor mRNA genomic biomarker (NETest) in blood.Ann Oncol. 2020; 31: 202-212
- Molecular genomic assessment using a blood-based mRNA signature (NETest) is cost-effective and predicts neuroendocrine tumor recurrence with 94% accuracy.Ann Surg. 2021; 274: 481-490
- Commonwealth neuroendocrine tumour research collaboration and the north American neuroendocrine tumor society guidelines for the diagnosis and management of patients with lung neuroendocrine tumors: an international collaborative endorsement and update of the 2015 European neuroendocrine tumor society expert consensus guidelines.J Thorac Oncol. 2020; 15: 1577-1598
- Current knowledge on diagnosis and staging of neuroendocrine tumors.Cancer Metastasis Rev. 2011; 30: 3-7
- Changing paradigms in the treatment of malignant pheochromocytoma.Cancer Control. 2011; 18: 104-112
- The evolution of neuroendocrine tumor treatment reflected by ENETS guidelines.Neuroendocrinology. 2018; 106: 357-365
- Adjuvant chemotherapy for patients with gastric neuroendocrine carcinomas or mixed adenoneuroendocrine carcinomas.Br J Surg. 2020; 107: 1163-1170
- Impact of Postoperative chemotherapy on the survival of patients with high-grade gastroenteropancreatic neuroendocrine carcinoma.Ann Surg Oncol. 2021; 28: 114-120
- PROMID Study Group, Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.J Clin Oncol. 2009; 27: 4656-4663
- Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial.Lancet Oncol. 2017; 18: 1652-1664
- Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study.Endocrine. 2021; 71: 502-513
- Lanreotide in metastatic enteropancreatic neuroendocrine tumors.N Engl J Med. 2014; 371: 224-233
- Long-term efficacy, survival, and safety of [177Lu-DOTA0, Tyr3] octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors.Clin Cancer Res. 2017; 23: 4617-4624
- Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors.N Engl J Med. 2017; 376: 125-135
- Peptide receptor radionuclide therapy in the management of advanced pheochromocytoma and paraganglioma: a systematic review and meta-analysis.Clin Endocrinol (Oxf). 2019; 91: 718-727
- Molecular imaging and radionuclide therapy of pheochromocytoma and paraganglioma in the era of genomic characterization of disease subgroups.Endocr Relat Cancer. 2019; 26: R627-R652
- Neuroendocrine neoplasms: evolving and future treatments.Curr Opin Endocr Metab Res. 2021; 19: 15-21
- Pulmonary carcinoid surface receptor modulation using histone deacetylase inhibitors.Cancers (Basel). 2019; 11: 767
- Combination of 5-fluorouracil with epigenetic modifiers induces radiosensitization, somatostatin receptor 2 expression, and radioligand binding in neuroendocrine tumor cells in vitro.J Nucl Med. 2019; 60: 1240-1246
- Efficacy and safety of high-specific-activity 131I-MIBG therapy in patients with advanced pheochromocytoma or paraganglioma.J Nucl Med. 2019; 60: 623-630
- Phase II trial of bevacizumab monotherapy in pancreatic neuroendocrine tumors.Pancreas. 2021; 50: 1435-1439
- A phase II trial of ziv-aflibercept in patients with advanced pancreatic neuroendocrine tumors.Pancreas. 2019; 48: 381-386
- Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.N Engl J Med. 2011; 364: 501-513
- Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial.J Clin Oncol. 2010; 28: 69
- Everolimus for advanced pancreatic neuroendocrine tumors.N Engl J Med. 2011; 364: 514-523
- Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study.The Lancet. 2016; 387: 968-977
- Updated efficacy and safety outcomes for patients with well-differentiated pancreatic neuroendocrine tumors treated with sunitinib.Target Oncol. 2021; 16: 27-35
- Novel and evolving therapies in the treatment of malignant phaeochromocytoma: experience with the mTOR inhibitor everolimus (RAD001).Horm Metab Res. 2009; 41: 697-702
- Phase 2 study of everolimus monotherapy in patients with nonfunctioning neuroendocrine tumors or pheochromocytomas/paragangliomas.Cancer. 2012; 118: 6162-6170
- Anti-tumour activity of everolimus and sunitinib in neuroendocrine neoplasms.Endocr Connections. 2019; 8: 641-653
- BRAFV600E mutations in high-grade colorectal neuroendocrine tumors may predict responsiveness to BRAF–MEK combination therapy.Cancer Discov. 2016; 6: 594-600
- Favorable response to immunotherapy in a pancreatic neuroendocrine tumor with temozolomide-induced high tumor mutational burden.Cancer Commun. 2020; 40: 746-751
- Surufatinib in combination with toripalimab in patients with advanced neuroendocrine carcinoma: results from a multicenter, open-label, single-arm, phase II trial.J Clin Oncol. 2021; 39: e16199
- A phase II trial of atezolizumab and bevacizumab in patients with advanced, progressive neuroendocrine tumors (NETs).Am Soc Clin Oncol. 2020; 38: 619
- Immunotherapy of ipilimumab and nivolumab in patients with advanced neuroendocrine tumors: a subgroup analysis of the CA209-538 clinical trial for rare cancers.Clin Cancer Res. 2020; 26: 4454-4459
- A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: high-grade neuroendocrine neoplasm cohort.Cancer. 2021; 127: 3194-3201
- 1157O A multi-cohort phase II study of durvalumab plus tremelimumab for the treatment of patients (pts) with advanced neuroendocrine neoplasms (NENs) of gastroenteropancreatic or lung origin: the DUNE trial (GETNE 1601).Ann Oncol. 2020; 31: S770-S771
- Immunotherapies for well-differentiated grade 3 gastroenteropancreatic neuroendocrine tumors: a new category in the World Health Organization classification.World J Gastroenterol. 2021; 27: 8123-8137
- Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study.Lancet Oncol. 2017; 18: 42-51
- Rovalpituzumab tesirine as a maintenance therapy after first-line platinum-based chemotherapy in patients with extensive-stage–SCLC: results from the phase 3 MERU study.J Thorac Oncol. 2021; 16: 1570-1581
- Efficacy and safety of rovalpituzumab tesirine compared with topotecan as second-line therapy in DLL3-high SCLC: results from the phase 3 TAHOE study.J Thorac Oncol. 2021; 16: 1547-1558
- All that glitters is not gold: the story of rovalpituzumab tesirine in SCLC.J Thorac Oncol. 2021; 16: 1429-1433
- A phase II trial of a histone deacetylase inhibitor panobinostat in patients with low-grade neuroendocrine tumors.Oncologist. 2016; 21: 785-786g
- Phase I trial of belinostat with cisplatin and etoposide in advanced solid tumors, with a focus on neuroendocrine and small cell cancers of the lung.Anticancer Drugs. 2018; 29: 457
- Targeting hdacs in pancreatic neuroendocrine tumor models.Cells. 2021; 10: 1408
- Pharmacological inhibition of class IIA HDACs by LMK-235 in pancreatic neuroendocrine tumor cells.Int J Mol Sci. 2018; 19: 3128
- PTPN3 is a potential target for a new cancer immunotherapy that has a dual effect of T cell activation and direct cancer inhibition in lung neuroendocrine tumor.Transl Oncol. 2021; 14: 101152
- Succinate mediates tumorigenic effects via succinate receptor 1: potential for new targeted treatment strategies in succinate dehydrogenase deficient paragangliomas.Front Endocrinol (Lausanne). 2021; 12: 129
- Targeting cyclooxygenase-2 in pheochromocytoma and paraganglioma: focus on genetic background.Cancers (Basel). 2019; 11
- Targeting NAD+/PARP DNA repair pathway as a novel therapeutic approach to SDHB-mutated cluster I pheochromocytoma and paraganglioma.Clin Cancer Res. 2018; 24: 3423-3432
- Belzutifan, a potent HIF2α inhibitor, in the Pacak–Zhuang syndrome.N Engl J Med. 2021; 385: 2059-2065
- Targeting renal cell carcinoma with a HIF-2 antagonist.Nature. 2016; 539: 112-117
- The significant reduction or complete eradication of subcutaneous and metastatic lesions in a pheochromocytoma mouse model after immunotherapy using mannan-BAM, TLR ligands, and anti-CD40.Cancers (Basel). 2019; 11: 654
- Chromogranin A as circulating marker for diagnosis and management of neuroendocrine neoplasms: more flaws than fame.Endocr Relat Cancer. 2018; 25: R11-R29
- Outcomes of advanced pulmonary large cell neuroendocrine carcinoma stratified by RB1 loss, SLFN11 expression, and tumor mutational burden.Am Soc Clin Oncol. 2018; 36: e20568
Article info
Footnotes
Funded by: No funding was used in the production of this article.
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
